Hospitality clause goes too far: Medicines Australia

In a new submission made late last month, MA, the peak body for the largest pharmaceutical companies operating in Australia, also warned that if the clause was imposed on the 18th edition, it was “more likely than not that member companies would reconsider seeking authorisation for Edition 18 and withdraw the authorisation application”.

MA’s 17th Code of Conduct was extended for an interim period which began last month – a week before the ACCC received the 23 January MA submission.  

The competition watchdog had pushed MA to propose a new reporting regime that required reporting of “transfers of value” of hospitality expenditure – including speaking fees, advisory board fees or sponsorship to attend a conference – on an aggregate basis.

But MA does not want to publish the total amount of cash spent on doctor hospitality and submitted that the ACCC does not have an “unfettered” ability